Assembly Biosciences (ASMB) Non-Current Debt (2010 - 2011)
Assembly Biosciences (ASMB) posted quarterly Non-Current Debt of $1.3 million for Q2 2011, up 3.86% quarter-over-quarter from $1.3 million in Q4 2010.
Powered by 
Analysis
Assembly Biosciences (ASMB) Non-Current Debt (2010 - 2011) Analysis & Trends
Assembly Biosciences' Non-Current Debt history runs 2 years deep, the most recent figure standing at $1.3 million for Q2 2011.
- In Q2 2011, Non-Current Debt changed N/A year-over-year to $1.3 million; the TTM figure through Jun 2011 stood at $1.3 million (changed N/A YoY), while the FY2010 annual figure was $1.3 million, changed N/A from the prior year.
- Non-Current Debt for Q2 2011 stood at $1.3 million, up from $1.3 million in the prior quarter.
- The five-year high for Non-Current Debt was $1.3 million in Q2 2011, with the low at $1.3 million in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Assembly Biosciences | 689.20 Mn | 368.83 Mn | - | - |